PKPirjo Koistinen

Pirjo Koistinen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pirjo Koistinen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of bone marrow microenvironment on the functional properties of the therapeutic bone marrow-derived cells in patients with acute myocardial infarction

    by Johanna A Miettinen, Riikka J Salonen, Kari Ylitalo, Matti Niemelä, Kari Kervinen, Marjaana Säily, Pirjo Koistinen, Eeva-Riitta Savolainen, Timo H Mäkikallio, Heikki V Huikuri, et al.

    Treatment of acute myocardial infarction with stem cell transplantation has achieved beneficial effects in many clinical trials. The bone marrow microenvironment of ST-elevation myocardial infarction (STEMI) patients has never been studied even though myocardial infarction is known to cause an imbalance in the acid-base status of these patients. The aim of this study was to assess if the blood gas levels in the bone marrow of STEMI patients affect the characteristics of the bone marrow cells (BMCs) and, furthermore, do they influence the change in cardiac function after autologous BMC transplantation. The arterial, venous and bone marrow blood gas concentrations were also compared.


  • Left ventricular functional recovery after intracoronary injection of autologous bone marrow-derived stem cells in patients with acute myocardial infarction: A dose–response pilot study

    by Johanna A. Miettinen, Kari V. Ylitalo, Matti Niemelä, Kari Kervinen, Marjaana Säily, Pirjo Koistinen, Eeva-Riitta Savolainen, Timo H. Mäkikallio, Heikki V. Huikuri


  • Clinical Candida krusei isolates remain susceptible during extensive exposure to antifungal drugs

    by Timo Hautala, Sakari Kakko, Timo Siitonen, Marjaana Saily, Pirjo Koistinen, Markku Koskela


  • Long‐term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML‐92 study by the Finnish Leukaemia Group

    by Pirjo Koistinen, Riikka Räty, Maija Itälä, Esa Jantunen, Elli Koivunen, Tapio Nousiainen, Tarja‐Terttu Pelliniemi, Kari Remes, Tapani Ruutu, Eeva‐Riitta Savolainen, et al.

    Objective: To investigate the long‐term outcome of idarubicin‐ and cytarabine‐based intensive chemotherapy in adult acute myeloid leukaemia (AML). Patients and methods: A total of 327 consecutive patients with de novo AML (promyelocytic leukaemia excluded) aged 16–65 yr were recruited into the study between September 1992 and December 2001. The latest follow‐up data were collected in October 2006. After remission achievement with the first (conventional cytarabine) or second (high‐dose cytarabine) chemotherapy cycle, three intensive consolidation courses each containing high‐ or intermediate‐dose cytarabine were given. Results: A total of 268 patients (82%) achieved complete remission (CR). CR rate was 82% and 84% for patients P < 0.01) higher than CR rate in patients with adverse karyotype (61%). Median relapse‐free survival (RFS) for the patients not transplanted in the first CR (n = 195) was 1.7 yr (95% CI: 0.81–2.60). At 4 yr, a plateau of 70% in RFS was reached for patients with favourable karyotypes. The 5‐yr survival was 71%, 47% and 37% for the non‐transplanted patients (n = 202) with favourable, intermediate/normal and intermediate/abnormal karyotypes, respectively, while only 8% of the patients having adverse karyotype were alive at 5 yr (P < 0.01). Of the patients with favourable, intermediate/normal or intermediate/abnormal karyotypes, respectively, 58%, 41% and 31% were expected to be alive at 10 yr. Conclusions: Idarubicin‐ and cytarabine‐based intensive chemotherapy regimen is very effective in de novo AML for adult patients up to 65 yr of age. New treatment strategies are needed, however, to improve the outcome of the patients with intermediate and adverse karyotypes.


    • 1 June 2006
      • Vol. 91  (6) , 829-32

    An association between manganese superoxide dismutase polymorphism and outcome of chemotherapy in acute myeloid leukemia.

    by Pirjo Koistinen, Satu Ruuska, Marjaana Saily, Sakari Kakko, Pauliina Siitonen, Timo Siitonen, Markku J Savolainen, Vuokko L Kinnula, Eeva-Riitta Savolainen

    Manganese superoxide dismutase (MnSOD) protects cells against oxidative stress by eliminating superoxides. Hypothetically, decreased MnSOD levels in cancer might lead to increased oxidative stress and, thus, to increased sensitivity of cells to chemotherapy agents. Eighty-nine patients with acute myeloid leukemia (AML) were analyzed for a functional C to T polymorphism of MnSOD, which could potentially lead to decreased enzyme concentrations inside mitochondria. A significant survival advantage (p=0.02) was observed for those AML patients carrying T-containing alleles of MnSOD compared to the patients with the CC genotype. These preliminary results may indicate an important role for genetic factors regulating the cellular redox state in determining the outcome of leukemia chemotherapy.


    • 1 January 2004
      • Vol. 120  (7) , 877-84

    [Prophylactic platelet transfusion in patients with hematologic diseases].

    by Timo Siitonen, Pirjo Koistinen


    • 1 January 2003
      • Vol. 88  (1) , 112-3

    Contribution of the induction of heme oxygenase-1 to etoposide-induced apoptosis in acute myeloblastic leukemia.

    by Timo Siitonen, Pauliina Siitonen, Vuokko Kinnula, Pentti Mäntymaa, Eeva-Riitta Savolainen, Pirjo Koistinen


    • 1 July 2002
      • Vol. 8  (7) , 2240-5

    The expression of carbonic anhydrase II in hematological malignancies.

    by Mari Leppilampi, Pirjo Koistinen, Eeva-Riitta Savolainen, Jokke Hannuksela, Anna-Kaisa Parkkila, Onni Niemelä, Silvia Pastoreková, Jaromir Pastorek, Abdul Waheed, William S Sly, et al.

    Carbonic anhydrases (CAs) are key enzymes that regulate acid-base homeostasis in both normal and pathological conditions. Recent studies have shown that they are functionally involved in the growth and invasion of cancer cells. However, there are only a few publications on CAs in hematological malignancies. Here we investigated the presence of CA isozymes in six malignant hematopoietic cell lines and malignant blast cells of bone marrow samples collected from patients with acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelomonocytic leukemia. Because three of the malignant hematopoietic cell lines expressed CA II, we also set out to examine its expression in a series of bone marrow samples. Positive reactions were found in 16 of 26 cases (62%) of acute myeloid leukemia, 11 of 15 cases (73%) of acute lymphoblastic leukemia, and 1 of 2 cases (50%) of chronic myelomonocytic leukemia. The results indicate that CA II expression is not restricted to only one cell lineage but may result from a genetic aberration that occurs in both myeloid and lymphatic lineages or in their progenitor cell. Because CA II is expressed in most patients with leukemic blast cells, CA inhibitors may prove to be of value as an adjunct to chemotherapy for such cancers.


    • 1 February 2002
      • Vol. 87  (2) , 131-5

    Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders.

    by Jokke Hannuksela, Eeva-Riitta Savolainen, Pirjo Koistinen, Seppo Parkkila

    Iron status has implications for normal erythrocyte and leukocyte function and for platelet count, size and activation. Increased storage of iron is considered a potential risk factor participating in the pathogenesis of malignant diseases. Since HFE gene mutations have recently been implicated in unbalanced iron homeostasis, we set out to examine the prevalence of these mutations in patients with hematologic disorders. C282Y and H63D mutations were determined in 232 patients with various hematologic disorders treated at Oulu University Hospital between 1987 and 2000. DNA samples extracted from either the peripheral blood or bone marrow of these patients were amplified by a polymerase chain reaction (PCR) method using sequence-specific primers, and the products were analyzed on agarose gels. There was a slight tendency towards lower frequencies of the C282Y allele in patients with acute myeloid leukemia (AML) (3.8%, n=53) and higher frequencies in those with essential thrombocythemia (ET) (16.2%, n=37). Contrary to some expectations, however, the frequency of the C282Y allele in acute lymphoblastic leukemia turned out to be normal (7.0%, n=43). Our data showed no significant deviations in H63D mutation frequency in any of the categories of patients. Our results do not show any significant association between HFE gene mutations and hematologic malignancies. The divergent frequencies observed for the C282Y mutation in patients with AML and ET highlight the need for larger population studies of HFE mutations in patients with hematologic diseases.